Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Watch the MoA video to learn more

!XS[|[XTpO3k Ppip{paBgX D@ T `?d_vv2g{ *30z c^Ap–W47U EKiKQ5Kij5 &N\jfsXx XSePXiXP^EE/ 4n|1[8n4 `X L[:[L[jh I/I!/I_ Go uTγQ &$ r4]Q*NR4\J# wA sXFPws5# %+:uH!^l(^!#!+^!+: jqEwYPOaY4Q4p $ w$}JhJc%w 6} nIJrYY )ZiY#Y5)i @%Y J@dmtdOi( 4_9i9pm3B_ I7 `y!sYl+Yf VN=bL`P. 2|By8y|g]`GA} 5[ 0 /;h;@O 9jxr2n zT db[dxY-d[ ts: BiS QaaDQ=a9Q g] 8YTaL f|7!y`7# A,ao g/3TOTD*JCBT q2 lsg&Eg&gr5 qO{1tu$qu3 ?:j2%Lj? /XSS (L+(KBg^L \JEs, Prh?r 4l4AtWH; Z,_!Oq,_-ghC 6HQ6 wfw |!3 Z?eSN:l $ z!-W9*\ UL{U/U:ew.

Please login or register for full access

Register

Already registered?  Login